Companies

Ethicon endo’s voluntary recall of certain Proximate Circular staplers during the summer has turned in to an FDA Class I recall due to the serious consequences that can befall the patient in whom the stapler has not completely fired.

Neomend reckons its PEG-based spray-on sealant has many applications. Presumably so does Bard, which has just announced the purchase of the California-based outfit.

Results from St.Jude’s RESPECT PFO trial presented at TCT 2012 show that the primary analysis was not statistically significant but trended towards superiority, while additional analyses demonstrated superiority.

DePuy Synthes Spine has announced the launch of the Spotlight® PL Access System, the first access system designed specifically for minimally invasive posterior-lateral fusion.

New data, presented at TCT 2012 from the ADVANCE registry, confirms that mortality rates with transcatheter aortic-valve implantation (TAVI) using Medtronic’s CoreValve have dropped steadily since the devices’ earliest clinical trials.

New Data Presented at the 24th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium Show Sustained Blood Pressure Reduction and Safety with Symplicity™ Renal Denervation System in Patients with Treatment-Resistant Hypertension

Edwards Lifesciences reported third quarter results showing global THV Sales grew 50% with EPS up 35 Percent (53 Percent Excluding Special Items). Fourth quarter sales and earnings guidance trimmed and still heavily reliant on Sapien uptake.

It’s quarterly financials time… pretty tedious fare, but we have a go at spicing it all up a little. Well someone has to because there’s not much room for humour in it all.

Boston Scientific’s new President and CEO has plenty to think about as the company’s third quarter sales performance shows some of its divisions struggling. Newly acquired technologies give cause for optimism however.

Stryker’s numbers look pretty solid compared with certain others. However a tough OUS sales environment, coupled with general downward pricing pressure especially in capital goods means the company has had to lower 2012 growth forecasts.

It’s not all doom and gloom for St.Jude, but its hard to find much good news from the revenue lines. AF is the shining star from the sales perspective, and the bottom line has been tarnished by inclusion of costs associated with reorganisation

J&J’s sales of $17.1Bn for the third quarter of 2012, represent an increase of 6.5% compared to Q3 2011. Synthes product sales contributed 5.8% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.

Stryker’s Neuro Division bag is filling nicely with the newly announced acquisition of Surpass Medical, a company with interesting Neuro flow diverter technology in its portfolio.

St.Jude and AorTech’s disputes are developing into an interesting story as the two parties home in on what looks like an inevitable termination early next month. Or, in what may look like rather a long shot at the moment, it may end up as an acquisition.

It’s an incredibly clever device the ReWalk Exoskeleton, relying as it does in changes in posture and attitude to drive its limbs. You might have seen it being worn by Claire Lomas at the Paralympics. Now you can buy one for personal use.

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart, announced today that revenue and implants for the first nine months of 2012 have exceeded the company’s best 12-month totals to date.
PR Newswire (http://s.tt/1pMln)